The AI-driven rare disease patient finder market is experiencing notable growth, projected to rise from $1.25 billion in 2024 to $1.62 billion in 2025, with a compound annual growth rate (CAGR) of 30.1%. This expansion is fueled by advancements in genomic sequencing, electronic health records (EHR), and telemedicine integration. The market is expected to reach $4.6 billion by 2029, driven by AI-powered analytics, clinical decision support systems, and increased investment in patient-centric platforms. Key players include UnitedHealth Group, Dassault Systemes, and GeneDx Holdings, among others. Regional growth is particularly strong in Asia-Pacific, while North America remains dominant. Innovations in natural language processing and synthetic data generation are anticipated, alongside improved patient recruitment solutions exemplified by Citeline’s PatientMatch. The report provides comprehensive market analysis, covering trends, competitive landscapes, and regional dynamics, essential for stakeholders in the healthcare and life sciences sectors seeking strategic insights.
Source link
Share
Read more